Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Fuji
Cerilliant
Medtronic
Argus Health
QuintilesIMS
Chinese Patent Office
Baxter
Daiichi Sankyo

Generated: June 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,178,563

« Back to Dashboard

Which drugs does patent 8,178,563 protect, and when does it expire?

Patent 8,178,563 protects ODOMZO and is included in one NDA.

This patent has fifty-seven patent family members in forty-four countries.
Summary for Patent: 8,178,563
Title:Compounds and compositions as hedgehog pathway modulators
Abstract: The invention provides a method for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula I.
Inventor(s): Gao; Wenqi (San Diego, CA), Jiang; Jiqing (San Diego, CA), Wan; Yongqin (Irvine, CA), Cheng; Dai (San Diego, CA), Han; Dong (San Diego, CA), Wu; Xu (San Diego, CA), Pan; Shifeng (San Diego, CA)
Assignee: IRM LLC (Hamilton, BM)
Application Number:12/299,290
Patent Claim Types:
see list of patent claims
Compound; Use;

Drugs Protected by US Patent 8,178,563

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Sun Pharma Global ODOMZO sonidegib phosphate CAPSULE;ORAL 205266-001 Jul 24, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y TREATMENT OF BASAL CELL CARCINOMA ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,178,563

PCT Information
PCT FiledMay 04, 2007PCT Application Number:PCT/US2007/068292
PCT Publication Date:November 15, 2007PCT Publication Number: WO2007/131201

International Family Members for US Patent 8,178,563

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal 2363393 ➤ Try a Free Trial
Portugal 2021328 ➤ Try a Free Trial
Peru 04182008 ➤ Try a Free Trial
New Zealand 572362 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Mallinckrodt
QuintilesIMS
Dow
Chubb
Citi
Boehringer Ingelheim
Covington
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.